How well do lipophilicity parameters, MEEKC microemulsion capacity factor, and plasma protein binding predict CNS tissue binding?

Journal of Pharmaceutical Sciences

Volumn 101, Issue 5, 2012, Pages 1932-1940

  Zamek Gliszczynski, Maciej J ^a   Sprague, Karen E ^a   Espada, Alfonso ^b   Raub, Thomas J ^a   Morton, Stuart M ^a   Manro, Jason R ^a   Molina Martin, Manuel ^b  

^a ELI LILLY AND COMPANY   (United States)

^b ELI LILLY AND COMPANY   (Spain)

Author keywords

CNS drug distribution; Pharmacokinetics; Pharmacokinetics pharmacodynamics; Protein binding

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; OCTANOL; PLASMA PROTEIN; WATER;

ANALYTICAL ERROR; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN; BRAIN FRACTION UNBOUND; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG POTENCY; DRUG STABILITY; FRACTIONATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MICROEMULSION; MICROEMULSION ELECTROKINETIC CHROMATOGRAPHY; MOLECULE; NONHUMAN; PARTITION COEFFICIENT; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN FOLDING; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; EMULSION; METABOLISM; MICELLAR ELECTROKINETIC CHROMATOGRAPHY; PROTEIN BINDING;

BLOOD PROTEINS; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY, MICELLAR ELECTROKINETIC CAPILLARY; EMULSIONS; HUMANS; PROTEIN BINDING;

EID: 84864317351     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23081     Document Type: Article

References (21)

1. Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. 2007. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: Assessment of unbound brain EC50, u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 323(1):346-355.
2. de Lange EC, Danhof M. 2002. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: Implications of the barriers between blood and brain. Clin Pharmacokinet 41(10):691-703.
3. Smith DA, Di L, Kerns EH. 2010. The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery. Nat Rev Drug Discov 9(12):929-939.
4. Graff CL, Pollack GM. 2004. Drug transport at the blood-brain barrier and the choroid plexus. Curr Drug Metab 5(1):95-108.
5. Kalvass JC, Maurer TS. 2002. Influence of nonspecific brain and plasma binding on CNS exposure: Implications for rational drug discovery. Biopharm Drug Dispos 23(8):327-338.
6. Kalvass JC, Maurer TS, Pollack GM. 2007. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35(4):660-666.
7. Maurer TS, Debartolo DB, Tess DA, Scott DO. 2005. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33(1):175-181.
8. Banker MJ, Clark TH, Williams JA. 2003. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92(5):967-974.
9. Zamek-Gliszczynski MJ, Ruterbories KJ, Ajamie RT, Wickremsinhe ER, Pothuri L, Rao MV, Basavanakatti VN, Pinjari J, Ramanathan VK, Chaudhary AK. 2011. Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. J Pharm Sci 100(6):2498-2507.
10. van Liempd S, Morrison D, Sysmans L, Nelis P, Mortishire-Smith R. 2011. Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding. J Lab Autom 16(1):56-67.
11. Wan H, Ahman M, Holmen AG. 2009. Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. J Med Chem 52(6):1693-1700.
12. Wan H, Holmen AG. 2009. High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery. Comb Chem High Throughput Screen 12(3):315-329.
13. Wong KS, Kenseth J, Strasburg R. 2004. Validation and long-term assessment of an approach for the high throughput determination of lipophilicity (log POW) values using multiplexed, absorbance-based capillary electrophoresis. J Pharm Sci 93(4):916-931.
14. Poole SK, Patel S, Dehring K, Workman H, Dong J. 2003. Estimation of octanol-water partition coefficients for neutral and weakly acidic compounds by microemulsion electrokinetic chromatography using dynamically coated capillary columns. J Chromatogr B Analyt Technol Biomed Life Sci 793(2):265-274.
15. Ertl P, Rohde B, Selzer P. 2000. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43(20):3714-3717.
16. Berry LM, Roberts J, Be X, Zhao Z, Lin MH. 2010. Prediction of V(ss) from in vitro tissue-binding studies. Drug Metab Dispos 38(1):115-121.
17. Zhang J, Shou WZ, Vath M, Kieltyka K, Maloney J, Elvebak L, Stewart J, Herbst J, Weller HN. 2010. An integrated bioanalytical platform for supporting high-throughput serum protein binding screening. Rapid Commun Mass Spectrom 24(24):3593-3601.
18. Wan H, Rehngren M. 2006. High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry. J Chromatogr A 1102(1-2):125-134.
19. Parikh HH, McElwain K, Balasubramanian V, Leung W, Wong D, Morris ME, Ramanathan M. 2000. A rapid spectrofluorimetric technique for determining drug-serum protein binding suitable for high-throughput screening. Pharm Res 17(5):632-637.
20. Liu X, Chen C, Hop CE. 2011. Do we need to optimize plasma protein and tissue binding in drug discovery? Curr Top Med Chem 11(4):450-466.
21. Liu X, Chen C. 2005. Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Devel 8(4):505-512.